Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis

Journal of Diabetes Investigation

Volumn 2, Issue 6, 2011, Pages 483-489

  Nakamura, Akinobu ^a   Yoneda, Masato ^a   Fujita, Koji ^a   Tajima, Kazuki ^a   Kikuchi, Kaori ^a   Nakajima, Atsushi ^a   Maeda, Shin ^a   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Hyperglycemia; Hyperinsulinemia; Non alcoholic steatohepatitis

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN RESISTANCE; JAPANESE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 84859855239     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00134.x     Document Type: Article

References (32)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-961.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832.
4. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
6. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
7. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798.
8. García-Monzón C, Martín-Pérez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-724.
9. Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
10. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145.
11. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
12. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
13. Iwasaki T, Nakajima A, Yoneda M, et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005; 28: 2486-2491.
14. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. World Hearth Organization, Geneva, 2006.
15. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
16. The International expert committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
17. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
20. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122: S37-S50.
21. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.
22. Medina J, Fernández-Salazar LI, García-Buey L, et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis Diabetes Care 2004; 27: 2057-2066.
23. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-1677.
24. Nakamura A, Sato K, Shirakawa J, et al. Long-term high-fat diet loading induced steatohepatitis and hepatocellular carcinoma in a mouse model. Diabetes 2010; 59(Suppl 1): A415 (Abstract).
25. Asano T, Watanabe K, Kubota N, et al. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol 2009; 24: 1669-1676.
26. Yoneda M, Iwasaki T, Fujita K, et al. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res 2007; 31: S15-S21.
27. Hamaguchi E, Takamura T, Sakurai M, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010; 33: 284-286.
28. Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994; 372: 182-186.
29. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380.
30. Inoue M, Iwasaki M, Otani T et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-1817.
31. Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 2010; 53: 2086-2088.
32. The DECODE study group on behalf of the Europe an Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.